Denali Therapeutics, Inc. (NASDAQ:DNLI) is considered one of the best oversold NASDAQ stocks to buy now, with an analyst maintaining a Buy rating and $32.00 price target. The company’s enzyme replacement therapy, DNL-310, has been accepted for priority review by the FDA for the treatment of Hunter Syndrome, offering potential advantages over current treatments due to its ability to cross the blood-brain barrier. Additionally, Denali Therapeutics, Inc. has a broader pipeline of Transport Vehicle-enabled therapies for various neurological conditions.

Read more at Yahoo Finance: BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target